Topic: ESOPRS 2021 ePoster sessions
Time: Sep 17, 2021 16:00 Amsterdam, Berlin, Rome, Stockholm, Vienna, 15:00 London
The zoom session will be a MEETING. Please turn off your camera and mic, unless prompted by the moderators during Q&A. When you enter the meeting there will be 2 BREAKOUT ROOMS. Please choose the appropriate room to join once you have joined the meeting.
The link details are below (you need to be logged in)
You are currently not logged in. If you have an account on this website please login to your account. Not registered yet? Signup here
(plain text version here)
Do prostaglandin analogue lash lengtheners cause eyelid fat and volume loss?
Author: Aaron Jamison
ePoster Number: 122
To identify whether periorbital fat/volume loss can be seen in the users of prostaglandin analogue (PGA) lash lengtheners.
An informal blinded randomised controlled trial comparing “before and after” colour photos of users of PGA-containing lash lengtheners (PGALL) (i.e., lengtheners containing bimatoprost, norbimatoprost, isopropyl cloprostenate, dechloro-dihydroxy-difluoro-ethylcloprostenolamide, or methylamido-dihydro-noralfaprostal), compared with users of non-PGALL (NPGALL), and false eyelashes (FL). Expert and layperson graders used a purpose-designed grading system to identify subtle signs of periorbital fat/volume loss over time.
Second attempt expert gradings achieved high levels of intrarater reliability and moderate levels of interrater reliability. Mean grading score was 8.2 in the PGALL group: NPGALL, 2.3 ; FL, 3.2. PGALL scores were significantly higher than in the NPGALL (p<0.001) and FL (p=0.017) ‘control’ groups, and there was no statistically significant difference between the two ‘control’ groups (p=0.634). The three periocular regions with greatest fat/volume loss were the upper lid pre-septal region (score of 1.20, out of 2.0), upper lid pre-tarsal region (1.20) and lower lid pre-tarsal region (1.13).
Our findings suggest that PGALL users develop periorbital fat loss, which can be appreciated both by expert graders and laypeople. It is important that consumers are made aware of the possibility of periorbital volume loss prior to commencing PGALLs. In many cases, the customer-facing product ingredient list contains no mention of PGA, which is only reported in a separate product information sheet. Greater clarity is needed in such products.
|First name||Last name||Base Hospital / Institution|
|Linda||Okafor||Queen Victoria Hospital, East Grinstead|
|Katja||Ullrich||Queen Victoria Hospital, East Grinstead|
|Raman||Malhotra||Queen Victoria Hospital, East Grinstead|
Abstract ID: 21-182